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(salvage therapy), 2nd-remission, 2nd-relapse, 2nd-progression,
3rd-line treatment (salvage therapy) and dead. RESULTS: The
direct medical cost included diagnostic and stratiﬁcation
USD$2,152.01 ($2,016.77–$2,287.26); 1st-line CHOP [7.19
cycles (6.97–7.42)] USD$841.17 ($813.03–$869.31); R-CHOP
[7.20 cycles (6.32–8.08)] USD$17,823.19 ($12,670.83–
$22,975.55); 1st-salvage treatment (Bone Marrow Transplant,
BEAM scheme) USD$56,174.10; 2nd-salvage treatment ICE-
Scheme USD$18,162.34, DHAP-Scheme USD$4,138.10;
ESHAP-Scheme USD$3,730.22; and monthly cost of support
therapy and follow-up USD$382.15 ($301.74–$462.57). The
estimated management cost at the ﬁfth year was USD$59,785.68
for R-CHOP and USD$52,966.70 for CHOP. The CE rate for the
use of R-CHOP vs CHOP was USD$6,526.54 for each free-
progression year, a clear trend toward the use of monoclonal
antibody inclusion. CONCLUSIONS: Long term results are fun-
damental for any evaluation of NHL treatment scheme. Under
this scenario, the increase in the free-progression survival and
global survival, with R-CHOP a CE ratio under one GDP per-
capita in Mexico (USD$7,785.89—A WHO accepted threshold)
for every free-progression year gained and it is evident that this
treatment is cost-effective.
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OBJECTIVES: To determine whether use of chelation therapy in
patients with refractory anemia (RA) related to myelodysplastic
syndrome (MDS) is cost-effective relative to no chelation in
transfusion-dependent patients. METHODS: A 10-year cohort
model with monthly cycles was built to predict the health and
economic implications for patients receiving chelation therapy
with 20 mg/kg deferasirox compared with no chelation. The
model included increased risk of death with no chelation; major
adverse events (e.g., cardiac disease) were assumed non-
differential, thus excluded, in the base analysis. Risk of death was
determined based on published prognostic data from chelated
(overall median survival = 115 months from diagnosis) and non-
chelated (median = 51 months) patients. Costs and utilities were
applied in each cycle by WHO Risk Classiﬁcation. Unit costs,
obtained from US cost data sources, were used to calculate the
costs of medication, management and transfusions. Risks of
death and complications, life expectancy, resource use, initial
utility value and decrease in utility due to complications were
taken from published literature. Costs were discounted at 3% per
year; beneﬁts were not discounted. RESULTS: In the base case
analysis, when initial utility value was taken as 0.6 and cost of
deferasirox was assumed to be $70/day, costs per patient were
estimated at $97,619 with deferasirox vs. $28,712 with no che-
lation. Deferasirox was predicted to increase QALYs by 1.43
years per patient, resulting in ICER = $48,172/QALY gained.
Increasing the initial utility value to 1 resulted in an ICER of
$28,903. CONCLUSIONS: Chelation therapy with deferasirox
is predicted to result in higher QALYs and substantially fewer
adverse events due to excess iron accumulation at a reasonable
cost. Resulting cost-effectiveness ratios are estimated to be within
acceptable limits.
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OBJECTIVES: The decision to use a drug ﬁrst-line instead of
second-line (salvage therapy) could have a signiﬁcant clinical
outcome and economic impact especially in rare diseases with
high treatment costs such as acquired haemophilia. The aim of
this study is to compare the cost-effectiveness of ﬁrst-line versus
second-line use of recombinant activated factor VII (rFVIIa) in
the management of severe bleeds in patients with acquired hae-
mophilia. The perspective of the study is that of the United States
hospital authorities. METHODS: We modelled the economic
impact of different treatment strategies reported from the only
existing compassionate-use database containing data from 38
patients with acquired haemophilia for whom rFVIIa was used in
the management of 78 severe bleeding episodes from 1990–1995.
RESULTS: In 14 bleeds, rFVIIa was used as the ﬁrst-line therapy
with 100% success in controlling the bleeds, while a success rate
of 75% was reported for 64 bleeding episodes in which rFVIIa
was used as a salvage therapy. The mean treatment cost of rFVIIa
as the ﬁrst-line therapy was $362,906 compared to $416,793
when rFVIIa was used as a salvage therapy. Furthermore, the cost
per effectively treated bleed for the second-line strategy was
$545,113 compared to $362,468 for ﬁrst-line use. CONCLU-
SIONS: Based on these results, rFVIIa, as a ﬁrst-line therapy, is
the cost-effective treatment option in the management of severe
bleeding episodes in acquired haemophilia patients as compared
to second-line treatment strategies.
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OBJECTIVES: Failed Back Surgery Syndrome (FBSS) is a chronic
neuropathic pain disorder characterized by persistent lower back
and/or leg pain after lumbar spine surgery. We are developing
a cost-effectiveness study evaluating Spinal Cord Stimulation
(SCS) treatment compared to conventional medical management
(CMM) in FBSS patients. Here we report the baseline cost and
health-related quality of life (HR-QoL) data from a societal
perspective. METHODS: A prospective, pre-post, observational
study is ongoing in nine Italian centers. Enrolled patients will be
followed for two years. A questionnaire was developed to collect
clinical (NRS—pain Numerical Rating Scale), economic (visits,
drugs, diagnostic-tests, hospitalizations, productivity losses,
medical aids), and quality of life (EQ-5D, SF-36 and Oswestry)
patient outcomes and productivity losses for caregivers.
RESULTS: Eighty patients were enrolled (mean age 58; 58%
female). The mean NRS valued in the year before enrolment was
7.6  1.5. The average total cost per patient per month was
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